title: Toxic multinodular goitre in a patient with generalized resistance to thyroid hormone who harbours the R429Q mutation in the thyroid hormone receptor beta gene.
abstract: The association of resistance to thyroid hormone (RTH) due to a receptor defect with toxic multinodular goitre or with carcinoma of the thyroid has not been previously reported. Previous histopathological studies of the thyroid gland in patients with RTH have revealed changes similar to multinodular goitre, probably due to continuous stimulation by TSH. We report here a case of generalized resistance to thyroid hormone associated with a multinodular goitre, which became toxic. The patient was a 46-year-old Japanese woman who noticed a goitre although she had no symptoms of thyrotoxicosis. Initial examination revealed elevated serum thyroid hormone levels and a normal TSH level. Ultrasonography disclosed a multinodular goitre with cystic lesions. Three years later, the patient complained that the goitre had become larger and that she had developed symptoms of thyrotoxicosis such as palpitation and hyperhydrosis. Progressive hyperthyroxinaemia with relatively suppressed TSH, increased radioiodine uptake and negative anti-TSH receptor antibodies led to the diagnosis of toxic multinodular goitre. Subtotal thyroidectomy was performed, and pathological examination revealed a micropapillary carcinoma within the multinodular goitre. Occurrence of thyroid carcinoma should be considered in RTH because its incidence is high in multinodular goitre. Molecular examination revealed the R429Q mutation in the thyroid hormone receptor beta gene, which is one of the mutations usually manifesting as the pituitary resistance phenotype. That thyrotoxic manifestations appeared only during toxic stage of multinodular goitre in this case suggests that the phenotype of this type of mutation can be dependent on the amount of thyroid hormone.
authors.affiliation: Division of Endocrinology and Metabolism, Showa University Hospital and Third Department of Internal Medicine, Showa University, School of Medicine, 1-5-8, Hatanodai, Shinagawa, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Taniyama
authors.forename: N
authors.initials: N
authors.lastname: Ishikawa
authors.forename: N
authors.initials: N
authors.lastname: Momotani
authors.forename: K
authors.initials: K
authors.lastname: Ito
authors.forename: Y
authors.initials: Y
authors.lastname: Ban
mesh_terms: D000596:Amino Acids / Q000652:urine; D015415:Biomarkers / Q000097:blood / Q000652:urine; D018265:Carcinoma, Papillary, Follicular / Q000150:complications* / Q000235:genetics / Q000378:metabolism; D005260:Female; D006044:Goiter, Nodular / Q000150:complications* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D011988:Receptors, Thyroid Hormone / Q000235:genetics*; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D013760:Tetrahydrocortisol / Q000652:urine; D013761:Tetrahydrocortisone / Q000652:urine; D013964:Thyroid Neoplasms / Q000150:complications* / Q000235:genetics / Q000378:metabolism; D013965:Thyroidectomy; D013974:Thyroxine / Q000378:metabolism*; D014284:Triiodothyronine
chemical_list: D000596:Amino Acids; D015415:Biomarkers; D011988:Receptors, Thyroid Hormone; D012738:Sex Hormone-Binding Globulin; D014284:Triiodothyronine; D013761:Tetrahydrocortisone; C015484:pyridinoline; D013760:Tetrahydrocortisol; D013974:Thyroxine